ArticleAntimicrobial resistance and infection control2019
Effective therapeutic regimens in two South Asian countries with high resistance to major
Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Beyond Low Prevalence: Exploring Antibiotic Resistance and Virulence Profiles in Sri Lankan Helicobacter pylori with Comparative Genomics.Microorganisms · 2025Article
- Article
- The Prevalence, Risk Factors, and Antimicrobial Resistance Determinants ofInfectious disease reports · 2024Article
- Review
- Molecular Characterization and Mutational Analysis of Clarithromycin- and Levofloxacin-Resistance Genes inInternational journal of molecular sciences · 2023Article
- Drug Resistance Patterns of Commonly Used Antibiotics for the Treatment ofTropical medicine and infectious disease · 2023Review
- Therapeutic Potential of Sitafloxacin as a New Drug Candidate forAntibiotics (Basel, Switzerland) · 2021Article
- Next Generation Sequencing for the Prediction of the Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2021Review
- Current status ofPeerJ · 2021Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- The Potential Benefits of Vonoprazan asPharmaceuticals (Basel, Switzerland) · 2020Review
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Efficacy of tailored second-line therapy ofGut pathogens · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 5 countries.
Funding
Abstract
Background: Nepal and Bangladesh have a high prevalence of Methods: We used the agar dilution method to determine the minimal inhibitory concentration of 5 alternative antibiotics against 42 strains from Nepal and 56 from Bangladesh and performed whole genome mutation analysis. Results: No resistance to furazolidone or rifabutin and a high susceptibility of sitafloxacin (95.2% in Nepal and 98.2% in Bangladesh) were observed. In contrast, resistance to rifaximin (52.4% in Nepal and 64.3% in Bangladesh) was high. Moreover, resistance to garenoxacin was higher in Bangladesh (51.6%) than in Nepal (28.6%, Conclusions: Rifabutin can be cautiously implemented as therapy for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.